LONDON, England, Oct. 6-- The Royal Pharmaceutical Society issued the following news: We have today welcomed news that the withdrawal of Priadel, a brand of lithium taken by people with bipolar ...

The Competition and Markets Authority (CMA) launched a competition law investigation into Essential Pharma last month because of suspicions that the firm may have abused its dominant position by ...

Nine health bodies, including the Royal College of Psychiatrists and Royal Pharmaceutical Society, have written a letter to U.K. Secretary of State for Health and Social Care Matt Hancock MP urging ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. A private equity owned drugmaker is under investigation by the UK’s competition watchdog after its threats to ...

Nine health bodies, including the Royal College of Psychiatrists and Royal Pharmaceutical Society, have written a letter to UK Secretary of State for Health and Social Care Matt Hancock MP urging him ...

The NHS could potentially be saved millions of pounds after the competition watchdog reached a deal to prevent a vital medication for bipolar patients being withdrawn from the market. The Competition ...

UK patients who use the common bipolar drug Priadel may have to brace themselves for a possible withdrawal of the drug from the market by its pharma company. Fortunately, such a move might be thwarted ...

A probe has been launched into suspected anti-competitive practices in the supply of a bipolar treatment used by around 50,000 patients across the UK. The Competition and Markets Authority (CMA) ...

The CMA is investigating whether Essential Pharma may have abused its dominant position by proposing to withdraw the supply lithium drug Priadel. A probe into the supply of a bipolar treatment used by ...